Fermenta Biotech Ltd
Fermenta Biotech Q1 FY27: Capex ₹110 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Fermenta Biotech Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8) - Revenue ex-real estate: INR 124.3 crore, down 12% YoY (Page 5) - Nutrition business: - Vitamin D3 – Human Nutrition: INR 76.5 cro EBITDA: INR 22.4 crore in Q1FY27, down 39% YoY; INR 22.3 crore ex-real estate, down 37% YoY (Page 5) - Operating Margin (EBITDA Margin): Not explicitly stated as a percentage, but from revenue of INR 126.2 crore, EBITDA margin ≈ 17.7% - Profit After Tax (PAT): INR 9.5 crore in Q1FY27, down 56% YoY (Page 5 and Page 8) - Year-on-Year Change: EBITDA down 39% YoY, PAT down 56% YoY (Page 5) - Margin Outlook: No explicit margin outlook or guidance provided in the presentation.
From Fermenta Biotech Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8)
- Revenue ex-real estate: INR 124.3 crore, down 12% YoY (Page 5)
- Nutrition business:
- Vitamin D3 – Human Nutrition: INR 76.5 crore, down 10% YoY but up 24% QoQ (Page 7)
- Vitamin D3 – Animal Nutrition: INR 12.6 crore, down 41% YoY and 45% QoQ (Page 7)
- Others (Nutrition): INR 11.0 crore, up 28% YoY and 16% QoQ (Page 7)
- Other APIs and Intermediates: INR 11.6 crore, up 18% YoY (Page 7)
- Green Chemistry Solutions / Enzymes: INR 2.3 crore, up 15% YoY (Page 7)
- Animal nutrition volumes fell 52% QoQ and 20% YoY; company focused on volume discipline over price (Page 5)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- ₹110 crore capex at Dahej for capacity committed to Spray-Dried Vitamin D3 Calcifediol scale-up (Page 16).
- Dahej plant referenced for integrated, advanced manufacturing scale alongside Kullu and Tirupati (Page 12, 11).
- Capacity scale-up at Dahej mentioned as a reason for increased employee costs ahead of the ramp-up (Page 9).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Fermenta Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech Ltd's management said in earlier quarters
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
- Q1 FY22 earnings call →
- Q1 FY22 earnings call →
- Q3 FY21 earnings call →
- Q2 FY21 earnings call →
- Q2 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Fermenta Biotech Ltd Q1 FY27 results?
Q1FY27 total revenue: INR 126.2 crore, down 13% YoY (Page 8) - Revenue ex-real estate: INR 124.3 crore, down 12% YoY (Page 5) - Nutrition business: - Vitamin D3 – Human Nutrition: INR 76.5 cro EBITDA: INR 22.4 crore in Q1FY27, down 39% YoY; INR 22.3 crore ex-real estate, down 37% YoY (Page 5) - Operating Margin (EBITDA Margin): Not explicitly stated as a percentage, but from revenue of INR 126.2 crore, EBITDA margin ≈ 17.7% - Profit After Tax (PAT): INR 9.5 crore in Q1FY27, down 56% YoY (Page 5 and Page 8) - Year-on-Year Change: EBITDA down 39% YoY, PAT down 56% YoY (Page 5) - Margin Outlook: No explicit margin outlook or guidance provided in the presentation.
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
₹110 crore capex at Dahej for capacity committed to Spray-Dried Vitamin D3 Calcifediol scale-up (Page 16).
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.